Drug Profile
Avacopan - ChemoCentryx/Vifor Fresenius Medical Care Renal Pharma
Alternative Names: CCX 168; TAVNEOS; Tavneos; VynpentaLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Developer Amgen; ChemoCentryx; Kissei Pharmaceutical; Medpace; Vifor Fresenius Medical Care Renal Pharma
- Class Amides; Anti-inflammatories; Cyclopentanes; Fluorinated hydrocarbons; Piperidines; Skin disorder therapies; Small molecules; Urologics
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis
Highest Development Phases
- Marketed Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Phase III Membranoproliferative glomerulonephritis
- Phase II Haemolytic uraemic syndrome; Hidradenitis suppurativa; IgA nephropathy
- No development reported Liver disorders
Most Recent Events
- 19 Mar 2024 Amgen plans a phase III trial in Anti-neutrophil cytoplasmic antibody-associated vasculitis (In children, In adolescents, Combination therapy) (PO) in July 2024 (NCT06321601)
- 10 Nov 2023 Efficacy and adverse event data from the phase III ADVOCATE trial in Anti-neutrophil cytoplasmic antibody-associated vasculitis presented at the ACR Convergence 2023 (ACR-2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Liver-disorders in USA (PO)